Amendments to the Claims:

Listing of the Claims:

1) (currently amended) A pharmaceutical composition for treating and/or preventing cancer comprising at least one anti-cancer agent~~, characterized in that said anti-cancer agent is associated in the composition with~~ bonded to at least one peptide ~~capable of carrying said agent into cancerous cells and preventing the occurrence of chemoresistance to said agent~~, said peptide comprising ~~complying with one of the following~~ a formula[s] (I)~~, (II) or (III)~~:

~~X_1-X_2-X_3-X_4-X_5-X_6-X_7-X_8-X_9-X_{10}-X_{11}-X_{12}-X_{13}-X_{14}-X_{15}-X_{16} (I)~~

~~wherein formula (I), the residues X_1 to X_{16} are amino acid residues, 6 to 10 of which are hydrophobic amino acids and X_6 is tryptophan,~~

BXXBXXXXBBBXXXXXXB (I) ~~(II)~~,

~~BXXXBXXXBXXXXBBXB (III),~~

wherein ~~formulas (II) and (III)~~:

- ~~the identical or different~~ a B group[s] ~~represent~~ includes an amino acid residue in which the lateral chain comprises a basic group, and

- ~~the identical or different~~ an X group[s] ~~represent~~ includes an aliphatic or aromatic amino acid residue,

wherein ~~the~~ a retro form of said formula (I)~~, (II), (III)~~ peptide[s][,] comprises ~~composed of~~ D and/or L configuration amino acids, or a fragment of said amino acids ~~composed of~~ comprising a sequence of at least 5 and, preferentially, at least 7 successive amino acids of said formula (I)~~, (II) or (III)~~ peptide[s].

2) (withdrawn) Composition according to claim 1, characterized in that in the formula (I) peptide, the hydrophobic amino acids are alanine, valine, leucine, isoleucine, proline, phenylalanine, tryptophan, tyrosine and methionine, and the other amino acids are:

— non—hydrophobic amino acids which may be non—polar amino acids such as glycine, or polar amino acids such as serine, threonine, cysteine, asparagine, glutamine, or

— acidic amino acids (aspartic or glutamic acid), or

— basic amino acids (lysine, arginine or histidine), or

— a combination of amino acids of these three categories.

3) (withdrawn) Composition according to any of claims 1 or 2,

characterized in that the formula (I) peptide comprises 6 hydrophobic amino acids and 10 non—hydrophobic amino acids.

4) (currently amended) Composition according to claim 1, characterized in that in the formula (I) ~~(II) or (III)~~ peptide[s]:

— B is selected from arginine, lysine, diaminoacetic acid, diaminobutyric acid, diaminopropionic acid, and ornithine, and

— X is selected from glycine, alanine, valine, norleucine, isoleucine, leucine, cysteine, cysteine^{Acm}, penicillamine, methionine, serine, threonine, asparagine, glutamine, phenylalanine, histidine, tryptophan, tyrosine, proline, Abu, carboxylic amino—1—cyclohexane acid, Aib, carboxylic 2-aminotetraline, 4—bromophenylanine, tert—Leucine, 4—chlorophenylalanine, beta-cyclohexyalanine, 3,4-dichlorophenyalanine, 4—fluorophenyalanine, homoleucine, beta—homoleucine, homophenyalanine, 4-methylphenyalanine, 1-naphthyalanine, 2—naphthyalanine, 4-nitrophenyalanine, 3—nitrotyrosine, norvaline, phenylglycine, 3-pyridyalanine, and [2-thienyl]alanine.

5) (withdrawn) Use of a compound complying with the following formula

(IV):

A $(-)_m$ $(B)_n$ (IV)

where

— A represents a peptide as defined above,

— B represents an anti—cancer agent,

— n is 1 or more, preferably up to 10 and advantageously up to 5,

- $(-)_m$ represents the linker between A and B, where m is 1 or more, preferably up to 10 and advantageously up to 5,

to prepare a drug for treating and/or preventing cancer without inducing chemoresistance.

6) (withdrawn) Use according to claim 5, characterized in that, in formula (IV) the linker $(-)_m$ between A and B is a covalent, hydrophobic or ionic bond, that may or may not be split in physiological media or inside the cell, or a combination of said bonds.